SECUKINUMAB 150 MG PROVIDES SUSTAINED IMPROVEMENT IN SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM THE PREVENT STUDY

PODDUBNYY, D., A. DEODHAR, X. BARALIAKOS, R. BLANCO, Eva DOKOUPILOVÁ, S. HALL, A. KIVITZ, M.G.H. VAN DE SANDE, A. STEFANSKA, P. PERTEL, H. RICHARDS and J. BRAUN. SECUKINUMAB 150 MG PROVIDES SUSTAINED IMPROVEMENT IN SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM THE PREVENT STUDY. 2021. Available from: https://dx.doi.org/10.1136/annrheumdis-2021-eular.143.

Basic information

Original name

SECUKINUMAB 150 MG PROVIDES SUSTAINED IMPROVEMENT IN SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM THE PREVENT STUDY

Authors

PODDUBNYY, D., A. DEODHAR, X. BARALIAKOS, R. BLANCO, Eva DOKOUPILOVÁ, S. HALL, A. KIVITZ, M.G.H. VAN DE SANDE, A. STEFANSKA, P. PERTEL, H. RICHARDS and J. BRAUN

Edition

2021

---

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Organization unit

Faculty of Pharmacy

DOI

http://dx.doi.org/10.1136/annrheumdis-2021-eular.143

UT WoS

000692649600565

Keywords in English

secukinumab, non-radiographic axial spodyloarthritis

Tags

rivok, ÚFT

Tags

International impact, Reviewed

---

Abstract

V originále

Axial spondyloarthritis (axSpA) is an inflammatory disease characterised by chronic back pain, and it comprises radiographic axSpA and non-radiographic axSpA (nr-axSpA).1 Secukinumab (SEC) 150 mg, with (LD) or without loading (NL), dose significantly improved the signs and symptoms of patients with nr-axSpA in the PREVENT (NCT02696031) study through Week 52.